At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
In Brief
A Phase 2 clinical trial evaluating brentuximab vedotin, bendamustine, and 2 other interventions for Hodgkin Disease and Peripheral T Cell Lymphoma. Completed, enrolled 131 participants across 54 sites in 2 countries.
Detailed Summary
This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them unable to have standard chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with other drugs.
Study Details
Timeline
Interventions
1.8 mg/kg every 3 weeks by IV infusion
70 mg/m\^2 by IV infusion on Days 1 and 2 of 3-week cycle
375 mg/m\^2 every 3 weeks by IV infusion
3 mg/kg every 3 weeks by IV infusion